Autonomix CEO Highlights IP Protection And Expansion Beyond Pancreatic Cancer Into Cardiovascular, Pulmonary, And Pain Management At Virtual Investor Connect

Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it recently participated in a Virtual Investor CEO Connect segment.

As part of the segment, Brad Hauser, CEO of Autonomix, outlined two key priorities shaping the Company's trajectory: strengthening its platform through intellectual property protection and evaluating opportunities beyond pancreatic cancer, including potential applications in cardiovascular, pulmonary and interventional pain management areas.